Literature DB >> 35061509

Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.

Antonio Di Meglio1,2, Julie Havas1, Davide Soldato1,3, Daniele Presti1,4, Elise Martin1, Barbara Pistilli1,2, Gwenn Menvielle5, Agnes Dumas6, Cecile Charles1, Sibille Everhard7, Anne-Laure Martin7, Charles Coutant8, Carole Tarpin9, Laurence Vanlemmens10, Christelle Levy11, Olivier Rigal12, Suzette Delaloge1,2, Nancy U Lin13, Patricia A Ganz14, Ann H Partridge13, Fabrice André1,2, Stefan Michiels15,16, Ines Vaz-Luis1,2.   

Abstract

PURPOSE: Fatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk. PATIENTS AND METHODS: Participants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498), collecting longitudinal data at diagnosis (before the initiation of any cancer treatment) and 1 (T1), 2 (T2), and 4 (T3) years after diagnosis. The main outcome was severe global fatigue at T2 (score ≥ 40/100, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30). Analyses at T3 were exploratory. Secondary outcomes included physical, emotional, and cognitive fatigue (EORTC Quality of Life Questionnaire-FA12). Multivariable logistic regression models retained associations with severe fatigue by bootstrapped Augmented Backward Elimination. Validation methods included 10-fold internal cross-validation, overoptimism-corrected area under the receiver operating characteristic curves, and external validation.
RESULTS: Among 5,640, 5,000, and 3,400 patients at T1, T2, and T3, respectively, the prevalence of post-treatment severe global fatigue was 35.6%, 34.0%, and 31.5% in the development cohort. Retained risk factors for severe global fatigue at T2 were severe pretreatment fatigue (adjusted odds ratio v no 3.191 [95% CI, 2.704 to 3.767]); younger age (for 1-year decrement 1.015 [1.009 to 1.022]), higher body mass index (for unit increment 1.025 [1.012 to 1.038]), current smoking behavior (v never 1.552 [1.291 to 1.866]), worse anxiety (v noncase 1.265 [1.073 to 1.492]), insomnia (for unit increment 1.005 [1.003 to 1.007]), and pain at diagnosis (for unit increment 1.014 [1.010 to 1.017]), with an area under the receiver operating characteristic curve of 0.73 (95% CI, 0.72 to 0.75). Receipt of hormonal therapy was a risk factor for severe fatigue at T3 (v no 1.448 [1.165 to 1.799]). Dimension-specific risk factors included body mass index for physical fatigue and emotional distress for emotional and cognitive fatigue.
CONCLUSION: We propose a predictive model to assess fatigue among breast cancer survivors, within a personalized survivorship care framework. This may help clinicians to provide early management interventions or to correct modifiable risk factors and offer more tailored monitoring and education to patients at risk of severe post-treatment fatigue.

Entities:  

Mesh:

Year:  2022        PMID: 35061509      PMCID: PMC8966972          DOI: 10.1200/JCO.21.01252

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  61 in total

1.  Fatigue trajectories during the first 8 months after breast cancer diagnosis.

Authors:  Hanne Bødtcher; Pernille Envold Bidstrup; Ingelise Andersen; Jane Christensen; Birgitte Goldschmidt Mertz; Christoffer Johansen; Susanne Oksbjerg Dalton
Journal:  Qual Life Res       Date:  2015-05-14       Impact factor: 4.147

Review 2.  Personalised care planning for adults with chronic or long-term health conditions.

Authors:  Angela Coulter; Vikki A Entwistle; Abi Eccles; Sara Ryan; Sasha Shepperd; Rafael Perera
Journal:  Cochrane Database Syst Rev       Date:  2015-03-03

3.  Inflammatory biomarkers for persistent fatigue in breast cancer survivors.

Authors:  Alicia Collado-Hidalgo; Julienne E Bower; Patricia A Ganz; Steve W Cole; Michael R Irwin
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

4.  Neuropathic Pain After Breast Cancer Treatment: Characterization and Risk Factors.

Authors:  Susana Pereira; Filipa Fontes; Teresa Sonin; Teresa Dias; Maria Fragoso; José Castro-Lopes; Nuno Lunet
Journal:  J Pain Symptom Manage       Date:  2017-08-08       Impact factor: 3.612

Review 5.  Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment.

Authors:  Chelsea K Osterman; Hanna K Sanoff; William A Wood; Megan Fasold; Jennifer Elston Lafata
Journal:  JCO Oncol Pract       Date:  2021-09-01

6.  One-year course of fatigue after post-operative radiotherapy in Norwegian breast cancer patients--comparison to general population.

Authors:  Randi J Reidunsdatter; Grethe Albrektsen; Marianne J Hjermstad; Toril Rannestad; Line M Oldervoll; Steinar Lundgren
Journal:  Acta Oncol       Date:  2012-12-04       Impact factor: 4.089

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.

Authors:  Stephanie R Land; Benjamin A Toll; Carol M Moinpour; Sandra A Mitchell; Jamie S Ostroff; Dorothy K Hatsukami; Sonia A Duffy; Ellen R Gritz; Nancy A Rigotti; Thomas H Brandon; Sheila A Prindiville; Linda P Sarna; Robert A Schnoll; Roy S Herbst; Paul M Cinciripini; Scott J Leischow; Carolyn M Dresler; Michael C Fiore; Graham W Warren
Journal:  Clin Cancer Res       Date:  2016-02-17       Impact factor: 12.531

9.  Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Authors:  Ethan Basch; Amylou C Dueck; Lauren J Rogak; Lori M Minasian; William Kevin Kelly; Ann M O'Mara; Andrea M Denicoff; Drew Seisler; Pamela J Atherton; Electra Paskett; Lisa Carey; Maura Dickler; Rebecca S Heist; Andrew Himelstein; Hope S Rugo; William M Sikov; Mark A Socinski; Alan P Venook; Douglas J Weckstein; Diana E Lake; David D Biggs; Rachel A Freedman; Charles Kuzma; Jeffrey J Kirshner; Deborah Schrag
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

10.  UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO).

Authors:  Fabrice Andre; Patrick Arveux; Ines Vaz-Luis; Paul Cottu; Christel Mesleard; Anne Laure Martin; Agnes Dumas; Sarah Dauchy; Olivier Tredan; Christelle Levy; Johan Adnet; Marina Rousseau Tsangaris
Journal:  ESMO Open       Date:  2019-09-08
View more
  5 in total

Review 1.  Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review.

Authors:  Louise André; Gabriel Antherieu; Amélie Boinet; Judith Bret; Thomas Gilbert; Rabia Boulahssass; Claire Falandry
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

2.  Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.

Authors:  Ines Vaz-Luis; Antonio Di Meglio; Julie Havas; Mayssam El-Mouhebb; Pietro Lapidari; Daniele Presti; Davide Soldato; Barbara Pistilli; Agnes Dumas; Gwenn Menvielle; Cecile Charles; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Sarah Dauchy; Suzette Delaloge; Nancy U Lin; Patricia A Ganz; Ann H Partridge; Fabrice André; Stefan Michiels
Journal:  J Clin Oncol       Date:  2022-03-15       Impact factor: 50.717

3.  A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design.

Authors:  Antonio Di Meglio; Elise Martin; Tracy E Crane; Cecile Charles; Aude Barbier; Bruno Raynard; Anthony Mangin; Olivier Tredan; Carole Bouleuc; Paul H Cottu; Laurence Vanlemmens; Carine Segura-Djezzar; Anne Lesur; Barbara Pistilli; Florence Joly; Thomas Ginsbourger; Bernadette Coquet; Iris Pauporte; Guillemette Jacob; Aude Sirven; Julia Bonastre; Jennifer A Ligibel; Stefan Michiels; Ines Vaz-Luis
Journal:  Trials       Date:  2022-03-04       Impact factor: 2.279

4.  Contraceptive Use in Premenopausal Women With Early Breast Cancer.

Authors:  Matteo Lambertini; Claudia Massarotti; Julie Havas; Barbara Pistilli; Anne-Laure Martin; Alexandra Jacquet; Charles Coutant; Florence Coussy; Asma Dhaini Mérimèche; Florence Lerebours; Christine Rousset-Jablonski; Christelle Jouannaud; Olivier Rigal; Marion Fournier; Patrick Soulie; Maria Alice Franzoi; Lucia Del Mastro; Ann H Partridge; Fabrice André; Ines Vaz-Luis; Antonio Di Meglio
Journal:  JAMA Netw Open       Date:  2022-09-01

5.  Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.

Authors:  Antonio Di Meglio; Julie Havas; Arnauld S Gbenou; Elise Martin; Mayssam El-Mouhebb; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Florence Joly; Suzette Delaloge; Patricia A Ganz; Fabrice André; Ann H Partridge; Lee W Jones; Stefan Michiels; Ines Vaz-Luis
Journal:  J Clin Oncol       Date:  2022-04-21       Impact factor: 50.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.